Data / Form D filings / AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc.: Form D filing
AN2 Therapeutics, Inc., a pharmaceuticals company in Menlo Park, CA, filed a Form D with the SEC in 2026. The latest, on March 25, 2026, reports $40 million sold of a $40 million offering to 16 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1300 EL CAMINO REAL, SUITE 100, Menlo Park, CA, 94025
- Phone
- (650) 331-9090
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1880438
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | New notice | $39,999,989 | $39,999,989 | 16 | Mar 10, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Eric Easom | Executive Officer, Director | |
| Joshua Eizen | Executive Officer | |
| Lucy Day | Executive Officer | |
| Sanjay Chanda | Executive Officer | |
| Joseph S. Zakrzewski | Director | |
| Kabeer Aziz | Director | |
| Rob Readnour | Director | |
| Gilbert Lynn Marks | Director | |
| Stephanie Wong | Director | |
| Patricia Martin | Director | |
| Melvin Spigelman | Director | |
| Margaret FitzPatrick | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Mar 23, 2026 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what AN2 Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.